Shandong Keyuan Pharmaceutical Co (301281) Fair Value & Analysis
Healthcare · CN · Market cap 5.5B CNY
Fair value as of: Jun 24, 2026
Analysis
Shandong Keyuan Pharmaceutical Co (301281) currently trades at ¥50.61, while our model-based Fair Value estimate is ¥7.63 — implying the stock looks roughly 84.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Shandong Keyuan Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and marketing of chemical raw materials and their preparations. It offers gliclazide; metformin hydrochloride; isosorbide mononitrate; isosorbide dinitrate; lansoprazole; mecobalamin; ropivacaine hydrochloride; isoflurane; fluoxetine hydrochloride; clemastine fumarate; chlorpheniramine maleate; esmolol hydrochloride; nicotinamide-tinidazole; amlexanox; nisoldipine; qupibutu; clarithromycin lactobionate; propafenone hydrochloride; potassium diclofenac; chlorzoxazone; esomeprazole sodium; palonosetron hydrochloride; dalafeng; piroxicam; phenylephrine; vildagliptin; parecoxib sodium; ruxolitinib hydrochloride; and lurasidone hydrochloride. The company was founded in 2004 and is headquartered in Jinan, China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Shandong Keyuan Pharmaceutical Co (301281) undervalued?
What is the fair value of 301281?
What is the quality score of 301281?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.